Infliximab

• 

  Subject Areas on Research

  • 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. 
  • A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. 
  • A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. 
  • A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab. 
  • Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. 
  • As Infliximab Use for Ulcerative Colitis Has Increased, so Has the Rate of Surgical Resection. 
  • Association of anemia and physical disability among patients with rheumatoid arthritis. 
  • Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. 
  • Case reports of heart failure after therapy with a tumor necrosis factor antagonist. 
  • Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. 
  • Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. 
  • Colonic Crohn Disease After Cardiac Transplantation: Case Report and Literature Review. 
  • Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. 
  • Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. 
  • Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. 
  • Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. 
  • Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. 
  • Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? 
  • Extra-intestinal Hodgkin's lymphoma in a Crohn's disease patient on long-term azathioprine and infliximab therapy. 
  • Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study. 
  • Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. 
  • Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab. 
  • High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa. 
  • Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases. 
  • Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. 
  • IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. 
  • Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. 
  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. 
  • Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. 
  • Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. 
  • Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. 
  • Infliximab for the treatment of adults with psoriasis. 
  • Infliximab for the treatment of early rheumatoid arthritis. 
  • Infliximab in active early rheumatoid arthritis. 
  • Infliximab maintenance therapy for fistulizing Crohn's disease. 
  • Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. 
  • Infliximab treatment for rheumatic disease: clinical and radiological efficacy. 
  • Infliximab treatment maintains employability in patients with early rheumatoid arthritis. 
  • Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry. 
  • Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis. 
  • Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. 
  • Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. 
  • Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. 
  • Progress in the treatment of rheumatoid arthritis. 
  • Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. 
  • Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. 
  • Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2). 
  • SARS-CoV-2-associated multisystem inflammatory syndrome in children: clinical manifestations and the role of infliximab treatment. 
  • Sclerosing mesenteritis successfully treated with a TNF antagonist. 
  • Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. 
  • The Future Is Now: Biologics for Non-Infectious Pediatric Anterior Uveitis. 
  • The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. 
  • Tides of inflammation: impact of biologics. 
  • Treatment Strategies for Deficiency of Adenosine Deaminase 2. 
  • Tumor necrosis factor blockers in rheumatoid arthritis. 
  • Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. 
  • Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis.